ERBB2 and breast cancer: Mashall et al. [10] designed and constructed a fusion protein of anti-ErbB2 scFv and CD28; this fusion protein could be used for targeting of breast cancer cells positive for ErbB2 expression, providing a stimulatory signal for activation of T cells Report of Vaishampayan et al. [11] provided a strong rationale for developing phase II trials to determine whether ATC armed with Her2Bi (aATC) are effective for treating castrate resistant prostate cancer.